ProZyme Inc. – Trademark Portfolio
Entity Type: 03
ProZyme Inc. holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 10 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 4 Nice Classification classes. Currently, 8 trademarks are registered. Notable registered marks include GLY-Q, GLY-X, GLYKO, PROZYME, and GLYKOPREP. The owner is based in San Leandro, CA.
1933 Davis St., Suite 207
San Leandro, CA 94577-125
Showing of trademarks Trademarks
Trademark Classifications
ProZyme Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does ProZyme Inc. have?
ProZyme Inc. has 13 U.S. trademarks filed with the USPTO. Of these, 8 registered, 2 abandoned, 3 cancelled.
What trademark classes does ProZyme Inc. file in?
ProZyme Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 9 (Computers & Electronics), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are ProZyme Inc.'s most well-known trademarks?
ProZyme Inc.'s registered trademark portfolio includes well-known marks such as GLY-Q, GLY-X, GLYKO, PROZYME, and GLYKOPREP. These are among 8 currently registered trademarks in the portfolio.
What is ProZyme Inc.'s trademark registration success rate?
ProZyme Inc. has a 62% trademark registration rate, with 8 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.